GlassScriptPhysician profile
Johnny Shih
NPI 1629432570
$1,214.48
in general payments reported to CMS, 2019-2025
25 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.56 · 2020: $52.72 · 2021: $18.44 · 2022: $262 · 2023: $338 · 2024: $94.81 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $135.34 | 2023-2025 | Inspire |
| Abbott Laboratories | $119.95 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $117.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $107.24 | 2020-2025 | Ozempic, Rybelsus, Tresiba |
| Amgen INC. | $99.72 | 2023-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $84.90 | 2022-2025 | Shingrix, Bexsero, Arexvy |
| Janssen Biotech, INC. | $56.73 | 2024 | Akeega, Erleada, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $55.58 | 2020-2025 | Airsupra |
| Lilly USA, LLC | $48.63 | 2022-2025 | Kisunla, Zepbound, Mounjaro |
| Pfizer INC. | $40.93 | 2022-2023 | |
| Dynavax Technologies Corporation | $38.46 | 2022-2023 | Heplisav-B |
| Biosense Webster, INC. | $38.12 | 2023 | Carto 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.25 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $30.75 | 2022-2023 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Dexcom, INC. | $30.54 | 2023-2025 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $29.25 | 2022 | |
| Esperion Therapeutics, INC. | $20.25 | 2025 | Nexletol |
| Genmab U.S., INC. | $18.75 | 2024 | Tivdak |
| Novartis Pharmaceuticals Corporation | $18.68 | 2022 | |
| Ibsa Pharma INC. | $17.12 | 2025 | Flector, Licart, Tirosint |
| Avvisto Therapeutics, LLC | $15.51 | 2025 | Cycloset |
| Boston Scientific Corporation | $15.50 | 2025 | Axonics |
| Abbvie INC. | $15.24 | 2023 | Qulipta |
| Idorsia Pharmaceuticals US INC | $13.34 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Shih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.